Neurolink is an early stage company developing a novel therapy for the treatment of epilepsy.

Nearly three million Americans suffer from epilepsy, a neurological condition characterized by seizures. One of the most common neurological diseases, epilepsy affects approximately 1% of the population - 1 in 26 people will have epilepsy in their lifetime. While current therapies exist to control symptoms, for many patients, there is no ideal treatment due to limited efficacy and undesirable side effects.